Van Diest Capital LLC Invests $788,000 in IQVIA Holdings Inc. $IQV

Van Diest Capital LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,494 shares of the medical research company’s stock, valued at approximately $788,000. IQVIA comprises 1.2% of Van Diest Capital LLC’s investment portfolio, making the stock its 18th largest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AMG National Trust Bank acquired a new stake in IQVIA in the third quarter valued at $3,713,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in shares of IQVIA in the 3rd quarter valued at about $7,368,000. Citigroup Inc. grew its stake in IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after purchasing an additional 475,557 shares in the last quarter. Dana Investment Advisors Inc. increased its holdings in IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock valued at $30,401,000 after buying an additional 24,854 shares during the last quarter. Finally, Strive Asset Management LLC bought a new position in IQVIA during the 3rd quarter worth approximately $17,447,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday. Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. HSBC set a $210.00 target price on shares of IQVIA in a report on Wednesday, June 3rd. Finally, Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $222.56.

IQVIA Trading Down 1.5%

Shares of NYSE:IQV opened at $168.14 on Friday. The company has a 50 day moving average of $173.72 and a 200-day moving average of $191.84. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $28.06 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.46 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.